HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up
Titel:
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up
Auteur:
Jackisch, Christian Hegg, Roberto Stroyakovskiy, Daniil Ahn, Jin-Seok Melichar, Bohuslav Chen, Shin-Cheh Kim, Sung-Bae Lichinitser, Mikhail Starosławska, Elżbieta Kunz, Georg Falcon, Silvia Chen, Shou-Tung Crepelle-Fléchais, Aulde Heinzmann, Dominik Shing, Mona Pivot, Xavier